Related Experiment Videos
Clozapine reduces rehospitalization among schizophrenia patients
S Pollack1, M G Woerner, A Howard
1Hillside Hospital, Division of Long Island Jewish Medical Center, Glen Oaks, NY 11004, USA.
Insights
Clozapine significantly reduced rehospitalization rates in schizophrenia patients compared to typical neuroleptics. This study confirms clozapine
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Clozapine is an atypical antipsychotic with reported benefits in reducing hospitalizations for schizophrenia patients.
- Previous studies suggest clozapine may decrease rehospitalization rates, but further evidence is needed.
Purpose of the Study:
- To evaluate the impact of clozapine treatment on rehospitalization rates in schizophrenia patients.
- To compare the rehospitalization rates of patients switched to clozapine versus those on typical neuroleptics.
Main Methods:
- A retrospective analysis of 81 schizophrenia patients at Hillside Hospital who switched from typical neuroleptics to clozapine.
- Comparison of inpatient hospitalization rates before and after clozapine initiation.
- Inclusion of an age- and gender-matched control group on typical neuroleptics.
Main Results:
- Patients on clozapine experienced a significant reduction in mean annual rehospitalizations from 2.03 to 0.56 (p < .001).
- The decrease in hospitalization rate for clozapine patients was significantly greater than for the control group (p < .001).
- A 95% confidence interval indicated clozapine's superiority, reducing rehospitalizations by 1.0-2.0 per year.
Conclusions:
- Clozapine treatment is associated with a substantial and statistically significant decrease in rehospitalization rates for schizophrenia patients.
- The findings support the use of clozapine for reducing inpatient stays in this patient population.
- Clozapine demonstrates superior efficacy over typical neuroleptics in managing schizophrenia and preventing hospital readmissions.
Abstract:
A number of studies have reported reduced rehospitalization for patients on clozapine. This article adds to that literature by mining the clozapine database at Hillside Hospital. The sample consisted of 81 schizophrenia patients who entered Hillside on a typical neuroleptic and then had their medication changed to clozapine. We ascertained the number of inpatient hospitalizations before starting clozapine and compared this with the number of hospitalizations after starting clozapine. We also followed an age- and gender-matched comparison group of other schizophrenia patients who entered Hillside at approximately the same time. Results indicate that the mean number of rehospitalizations while on a typical neuroleptic was 2.03 (1.93)/year, whereas it was only .56 (.97/year after the commencement of clozapine treatment; t(80) = 5.78, p < .001. A 95% confidence interval for the superiority of clozapine over standard neuroleptic treatment as measured in rehospitalizations/year is (1.0, 2.0). The decrease in hospitalization rate of .4 (1.6)/year (pre-index date minus post-index date) for the comparison group was also statistically significant [t(80) = 2.3, p < .03]; the 95% confidence interval for this decrease over time is (.1, .8). The pre-post change was much greater for the clozapine patients than comparison patients. A 2 x 2 repeated measures analysis of variance (ANOVA) contrasting the comparison group to the clozapine patients both before and after the index date indicates a significant time by group interaction (F(1.80) = 22.35, p < .001), thus documenting the greater relative decrease in rehospitalization rate in the clozapine group.